Wayne A. Border
#136,848
Most Influential Person Now
Wayne A. Border's AcademicInfluence.com Rankings
Wayne A. Borderphilosophy Degrees
Philosophy
#6958
World Rank
#10091
Historical Rank
Ontology
#67
World Rank
#77
Historical Rank
Logic
#4038
World Rank
#5281
Historical Rank
Wayne A. Borderbiology Degrees
Biology
#9434
World Rank
#12643
Historical Rank
Biochemistry
#1440
World Rank
#1564
Historical Rank
Download Badge
Philosophy Biology
Wayne A. Border's Degrees
- PhD Biochemistry Stanford University
- Doctorate Medicine Stanford University
Why Is Wayne A. Border Influential?
(Suggest an Edit or Addition)Wayne A. Border's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Transforming Growth Factor β in Tissue Fibrosis (1994) (2920)
- Transforming growth factor beta in tissue fibrosis. (1994) (1352)
- Transforming growth factor-beta in disease: the dark side of tissue repair. (1992) (1172)
- Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. (1994) (1048)
- Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1 (1990) (1028)
- Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease (1992) (1018)
- Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. (1994) (1000)
- Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. (1993) (816)
- Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. (1990) (563)
- Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney (1996) (488)
- Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. (1998) (455)
- Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. (2006) (443)
- Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. (1994) (437)
- Expression of transforming growth factor-β isoforms in human glomerular diseases (1996) (405)
- Transforming growth factor-beta regulates production of proteoglycans by mesangial cells. (1990) (376)
- TGF-β in kidney fibrosis: A target for gene therapy (1997) (362)
- Production of extracellular matrix by glomerular epithelial cells is regulated by transforming growth factor-beta 1. (1992) (262)
- Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. (2007) (254)
- Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. (1998) (234)
- Role of transforming growth factor-beta 1 in experimental chronic cyclosporine nephropathy. (1996) (230)
- Induction of membranous nephropathy in rabbits by administration of an exogenous cationic antigen. (1982) (229)
- Antitubular basement-membrane antibodies in methicillin-associated interstitial nephritis. (1974) (228)
- Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. (1992) (198)
- Nehprotic syndrome with glomerular mesangial IgM deposits. (1978) (177)
- Nitric oxide mediates immunologic injury to kidney mesangium in experimental glomerulonephritis. (1995) (172)
- Transforming growth factor-beta and angiotensin II: the missing link from glomerular hyperfiltration to glomerulosclerosis? (1995) (165)
- TGF-beta in kidney fibrosis: a target for gene therapy. (1997) (154)
- Expression of transforming growth factor-beta isoforms in human glomerular diseases. (1996) (153)
- TGF-β isoforms in renal fibrogenesis (2003) (151)
- Gene therapy by transforming growth factor-beta receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis. (1999) (149)
- Transforming growth factor-beta and matrix protein expression in acute and chronic rejection of human renal allografts. (1995) (146)
- Cytokines in kidney disease: the role of transforming growth factor-beta. (1993) (145)
- Coordinated expression of beta 1 integrins and transforming growth factor-beta-induced matrix proteins in glomerulonephritis. (1993) (138)
- A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. (2003) (138)
- Curcumin blocks multiple sites of the TGF-β signaling cascade in renal cells (2004) (132)
- Angiotensin II in renal fibrosis: should TGF-beta rather than blood pressure be the therapeutic target? (1997) (131)
- Evidence that TGF-β should be a therapeutic target in diabetic nephropathy (1998) (128)
- Correlation and predictive accuracy of circulating immune complexes with disease activity in patients with systemic lupus erythematosus. (1980) (126)
- Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells. (1997) (119)
- Combining TGF-beta inhibition and angiotensin II blockade results in enhanced antifibrotic effect. (2004) (103)
- Clinical and antibody responses after influenza immunization in systemic lupus erythematosus. (1978) (100)
- Transforming growth factor beta in diabetic nephropathy. (1996) (100)
- Dietary protein restriction rapidly reduces transforming growth factor beta 1 expression in experimental glomerulonephritis. (1991) (99)
- Electrical charge. Its role in the pathogenesis and prevention of experimental membranous nephropathy in the rabbit. (1983) (98)
- TGF-beta isoforms in renal fibrogenesis. (2003) (95)
- Cytokines and L-arginine in renal injury and repair. (1994) (93)
- Antagonists of transforming growth factor-beta: a novel approach to treatment of glomerulonephritis and prevention of glomerulosclerosis. (1992) (93)
- Changes in heparan sulfate correlate with increased glomerular permeability. (1988) (86)
- Distinguishing minimal-change disease from mesangial disorders. (1988) (82)
- Angiotensin II, TGF-β and renal fibrosis (2001) (82)
- Detection of circulating immune complexes in patients with glomerulonephritis. (1977) (81)
- Angiotensin II blockade and low-protein diet produce additive therapeutic effects in experimental glomerulonephritis. (2000) (81)
- A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy. (2008) (79)
- In vivo interactions of TGF-β and extracellular matrix (1992) (77)
- Transforming Growth Factor in Diabetic Nephropathy (1996) (75)
- Extracellular matrix/growth factor interactions. (1992) (74)
- L-arginine may mediate the therapeutic effects of low protein diets. (1995) (73)
- Increased levels of transforming growth factor-beta in HIV-associated nephropathy. (1999) (73)
- Infusion of angiotensin-(1-7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis. (2010) (72)
- Enalapril and low protein reverse chronic puromycin aminonucleoside nephropathy. (1990) (71)
- Renal damage with intestinal bypass. (1978) (70)
- Transforming growth factor-beta 1 induces extracellular matrix formation in glomerulonephritis. (1990) (70)
- Transforming growth factor-beta and the pathogenesis of glomerular diseases. (1994) (69)
- Curcumin blocks multiple sites of the TGF-beta signaling cascade in renal cells. (2004) (64)
- Targeting TGF–β for treatment of disease (1995) (63)
- Receptor-dependent prorenin activation and induction of PAI-1 expression in vascular smooth muscle cells. (2008) (62)
- TGF-beta: a cytokine mediator of glomerulosclerosis and a target for therapeutic intervention. (1995) (62)
- Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy. (1998) (62)
- Curcumin blocks fibrosis in anti-Thy 1 glomerulonephritis through up-regulation of heme oxygenase 1. (2005) (61)
- Fibrosis linked to TGF-beta in yet another disease. (1995) (57)
- IgA antibasement membrane nephritis with pulmonary hemorrhage. (1979) (57)
- Extracellular matrix and glomerular disease. (1989) (57)
- Role of proteoglycans and cytoskeleton in the effects of TGF-beta 1 on renal proximal tubule cells. (1993) (56)
- Transforming growth factor-β in human glomerular injury (1997) (55)
- Aldosterone and TGF-beta1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells. (2008) (53)
- t-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis. (2001) (50)
- Therapeutic strategies to halt renal fibrosis. (2002) (49)
- L-Arginine supplementation increases mesangial cell injury and subsequent tissue fibrosis in experimental glomerulonephritis. (1999) (48)
- Increased expression of transforming growth factor-beta in renal disease. (1994) (48)
- Partial lipodystrophy, C3 nephritic factor and clinically inapparent mesangiocapillary glomerulonephritis. (1977) (47)
- Angiotensin II, TGF-beta and renal fibrosis. (2001) (46)
- From rats to man: a perspective on dietary L-arginine supplementation in human renal disease. (1999) (44)
- Changes in glomerular heparan sulfate in puromycin aminonucleoside nephrosis. (1987) (43)
- Myeloma kidney. An immunomorphogenetic study of renal biopsies. (1980) (42)
- Immune complex detection in glomerular diseases. (1979) (41)
- Transforming growth factor-beta and extracellular matrix deposition in the kidney. (1994) (39)
- Renal biopsy diagnosis of clinically silent multiple myeloma. (1980) (38)
- Interstitial Tamm-Horsfall protein in rejecting renal allografts. Identification and morphologic pattern of injury. (1984) (37)
- Tandem antifibrotic actions of L-arginine supplementation and low protein diet during the repair phase of experimental glomerulonephritis. (2000) (36)
- Circulating immune complexes in adults with idiopathic nephrotic syndrome (1980) (36)
- L-arginine metabolism in immune-mediated glomerulonephritis in the rat. (1996) (36)
- Failure of heparin to affect two types of experimental glomerulonephritis in rabbits. (1975) (36)
- Maximizing hemodynamic-independent effects of angiotensin II antagonists in fibrotic diseases. (2001) (35)
- Immune complexes, gallium lung scans, and bronchoalveolar lavage in idiopathic interstitial pneumonitis-fibrosis. (1983) (35)
- Henoch-Schönlein purpura: simultaneous demonstration of IgA deposits in involved skin, intestine, and kidney. (1982) (35)
- L-arginine supplementation accelerates renal fibrosis and shortens life span in experimental lupus nephritis. (2003) (34)
- Transforming growth factor-beta in glomerular injury. (1994) (33)
- Antigenic changes as a determinant of immune complex localization in the rat glomerulus. (1981) (33)
- [12] Role of transforming growth factor β and decorin in controlling fibrosis (1994) (32)
- Combining angiotensin II blockade and renin receptor inhibition results in enhanced antifibrotic effect in experimental nephritis. (2011) (31)
- Circulating immune complexes in rats with autologous immune complex nephritis. (1980) (30)
- Non-specificity of circulating immune complexes in patients with acute and chronic liver disease. (1980) (29)
- Transforming growth factor‐&bgr; in human glomerular injury (1997) (29)
- Functional renin receptors in renal mesangial cells (2007) (28)
- In vivo interactions of TGF-beta and extracellular matrix. (1992) (27)
- Noninhibitory PAI-1 enhances plasmin-mediated matrix degradation both in vitro and in experimental nephritis. (2006) (25)
- Crescentic glomerulonephritis: immune vs. nonimmune mechanisms. (1981) (25)
- Targeting reduction of proteinuria in glomerulonephritis: Maximizing the antifibrotic effect of valsartan by protecting podocytes (2014) (25)
- Nephritic factor: Description of a new quantitative assay and findings in glomerulonephritis. (1976) (24)
- Failure of angiotensin converting enzyme inhibition to affect the course of chronic puromycin aminonucleoside nephropathy. (1987) (24)
- Goodpasture syndrome treated with immunosuppression and plasma exchange. (1977) (23)
- Targeting TGF-beta for treatment of disease. (1995) (23)
- Mesangial proliferative glomerulonephritis (1982) (22)
- Mechanisms underlying the antifibrotic properties of noninhibitory PAI-1 (PAI-1R) in experimental nephritis. (2009) (21)
- Hypersensitivity phenomena and the kidney: role of drugs and environmental agents. (1985) (20)
- Anticoagulants are of little value in the treatment of renal disease. (1984) (19)
- In situ formation of subepithelial immune complexes in the rabbit glomerulus: requirement of a cationic antigen. (1984) (18)
- Perspectives on blockade of TGFβ overexpression (2006) (17)
- Receptor-mediated nonproteolytic activation of prorenin and induction of TGF-β1 and PAI-1 expression in renal mesangial cells. (2012) (17)
- From serum sickness to cytokines: advances in understanding the molecular pathogenesis of kidney disease. (1993) (16)
- Angiotensin II and progressive renal insufficiency (2002) (15)
- Genes expressed by the kidney, but not by bone marrow-derived cells, underlie the genetic predisposition to progressive glomerulosclerosis after mesangial injury. (2003) (15)
- Glomerulonephritis with mesangial IgM deposits (1982) (14)
- Role of transforming growth factor beta and decorin in controlling fibrosis. (1994) (14)
- Role of TGF-beta 1 in experimental glomerulonephritis. (1991) (14)
- The binding reactions of antibodies specific for the 2,6-dinitrophenyl group. (1969) (13)
- Perspectives on blockade of TGFbeta overexpression. (2006) (11)
- Targeting TGF-beta overexpression: maximizing the antifibrotic actions of angiotensin II blockade in anti-Thy1 glomerulonephritis. (1999) (11)
- Glomerulonephritis in systemic lupus erythematosus. (1981) (10)
- False-negative anti-DNA antibody activity in infantile systemic Lupus erythematosus (SLE) (1984) (10)
- The 260-kDa transforming growth factor (TGf)-β binding protein in rat glomeruli is a complex comprised of 170- and 85-kDa TGF-β binding proteins (1992) (10)
- Aldosterone and Epithelial Na Channels Aldosterone and TGF-1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells (2008) (8)
- TRANSFORMING GROWTH FACTOR BETA REGULATES PRODUCTION OFPROTEOGLYCANS BY MESANGIAL CELLS (1990) (8)
- Gallium citrate Ga 67 scanning in acute renal failure. (1995) (8)
- The kidney in hypergammaglobulinemic purpura. (1987) (7)
- Cefoxitin-induced interstitial nephritis. (1981) (6)
- Cell elastimetry in the detection of antineutrophil antibodies. (1981) (6)
- Role of immunoglobulin class in mediation of experimental mesangial glomerulonephritis. (1983) (6)
- Effect of maximal reduction of angiotensin in renal fibrosis: bad news-good news from a pediatric mouse. (2000) (6)
- Effect of angiotensin II on the expression of plasminogen activator inhibitor -1 in rat mesangial cells (1994) (5)
- The 260-kDa transforming growth factor (TGF)-beta binding protein in rat glomeruli is a complex comprised of 170- and 85-kDa TGF-beta binding proteins. (1992) (3)
- Antigenic charge as a factor in resistance to immunosuppressive therapy. (1988) (3)
- Role of Antigen and Antibody Charge in Immune Complex Disease (1984) (2)
- Expression of transforming growth factor 18 is elevated in human and experimental diabetic nephropathy (2005) (2)
- Role of TGF‐β1 in Experimental Glomerulonephritis (2007) (2)
- Molecular and cellular biological techniques in the study of glomerular diseases. (1992) (2)
- Electropharmacologic modulation of in situ complex formation in experimental membranous nephropathy (MN) (1982) (2)
- Integrative Aspects of Renal Endocrinology Receptor-mediated nonproteolytic activation of prorenin and induction of TGF-1 and PAI-1 expression in renal mesangial cells (2012) (2)
- The Management of the Nephrotic Syndrome (1984) (1)
- The Pathogenesis of Autologous Immune Complex Glomerulonephritis in Rats (1983) (1)
- Drug-Induced Nephritides Immediate Hypersensitivity Mechanism (1982) (1)
- Nephrotic syndrome in a 47-year-old woman with monoclonal gammopathy. (1982) (0)
- Drug-Induced Nephritides (1982) (0)
- Antigenic Charge asaFactor inResistance to Immunosuppressive Therapy (1988) (0)
- Glomerular acceptors: New thoughts about the pathogenesis of immune complex glomerulonephritis (1984) (0)
- Presence of circulating immune complexes in acute and chronic liver disease (1978) (0)
- Diagnosis and management of Goodpasture's syndrome (1981) (0)
- Contents, Vol. 36, 1984 (1984) (0)
- Circulating immune complexes in adults with idiopathic nephrotic syndrome. Collaborative Study of the Adult Idiopathic Nephrotic Syndrome. (1980) (0)
- Inhibiteurs de facteurs regulateurs cellulaires et procedes de prevention ou de reduction de la formation de cicatrices (1992) (0)
- Use of decorin or biglycan for the preparation of a medicament for the treatment of diabetes-related conditions (1992) (0)
- The effects of heparin anticoagulation on the course of chronic serum sickness nephritis and anti GBM nephritis in rabbits (1974) (0)
- Goodpasture’s Syndrome (1998) (0)
- Subject Index, Vol. 36, 1984 (1984) (0)
- aminonucleo side nephropathy (1990) (0)
- THERAPIE GENIQUE ANTI-FACTEUR DE CROISSANCE TRANSFORMANT $g(b) (1996) (0)
- Chest Diseases-Epitomes of Progress: Diagnosis and Management of Goodpasture's Syndrome. (1981) (0)
- Results of Immune Complex Detection in Human Glomerular Diseases (1983) (0)
- Inhibition of transforming growth factor for the prevention of the accumulation of extracellular matrix (1990) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Wayne A. Border?
Wayne A. Border is affiliated with the following schools:
